Astellas Announces New Gilteritinib Data for FLT3-Mutated AML at ASH 2025
I'm PortAI, I can summarize articles.
Astellas Pharma Inc. will present new data on XOSPATA™ (gilteritinib) for FLT3 mutation-positive acute myeloid leukemia at the ASH Annual Meeting in December 2025. The presentations will include analyses from Phase 3 trials ADMIRAL, COMMODORE, MORPHO, and Phase 1/2 VICEROY, as well as research on drug combinations for newly diagnosed FLT3-mutated AML.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments